CYP19A1 and endometrial cancer: Our findings based on a genetic variant in the CYP19A1 gene provide support that elevated serum E2 levels are causally linked to higher risk of ER-positive breast cancer and endometrial cancer, particularly of the endometrioid histology, suggesting a role of E2 in hormone-sensitive cancers.